• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾脏病和终末期肾病患者的血脂异常

Dyslipidemia in patients with chronic and end-stage kidney disease.

作者信息

Omran Jad, Al-Dadah Ashraf, Dellsperger Kevin C

出版信息

Cardiorenal Med. 2013 Oct;3(3):165-177. doi: 10.1159/000351985. Epub 2013 Jul 13.

DOI:10.1159/000351985
PMID:24454313
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3884190/
Abstract

In this review, we discuss the physiology, diagnosis and treatment of dyslipidemia in patients with chronic and end-stage renal disease. The recent important clinical trials in patients with chronic kidney disease and dyslipidemia are reviewed. Because of the lack of evidence in treating lipid abnormalities in this specific patient population, we propose that future studies should focus on the pathophysiological mechanisms and treatment of dyslipidemia in this special patient population.

摘要

在本综述中,我们讨论了慢性和终末期肾病患者血脂异常的生理学、诊断和治疗。对近期慢性肾病合并血脂异常患者的重要临床试验进行了综述。由于在这一特定患者群体中治疗血脂异常缺乏证据,我们建议未来的研究应聚焦于这一特殊患者群体血脂异常的病理生理机制和治疗。

相似文献

1
Dyslipidemia in patients with chronic and end-stage kidney disease.慢性肾脏病和终末期肾病患者的血脂异常
Cardiorenal Med. 2013 Oct;3(3):165-177. doi: 10.1159/000351985. Epub 2013 Jul 13.
2
Statins for treatment of dyslipidemia in chronic kidney disease.他汀类药物用于治疗慢性肾脏病中的血脂异常。
Perit Dial Int. 2006 Sep-Oct;26(5):523-39.
3
The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.非高密度脂蛋白在管理5期慢性肾脏病血脂异常中的作用
Clin Nephrol. 2006 Nov;66(5):336-47. doi: 10.5414/cnp66336.
4
Dyslipidemia in patients with chronic kidney disease: etiology and management.慢性肾脏病患者的血脂异常:病因与管理
Int J Nephrol Renovasc Dis. 2017 Feb 7;10:35-45. doi: 10.2147/IJNRD.S101808. eCollection 2017.
5
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.肾脏病相关血脂异常中 PCSK9 和脂蛋白受体的新方面。
Cell Signal. 2019 Mar;55:53-64. doi: 10.1016/j.cellsig.2018.12.001. Epub 2018 Dec 12.
6
Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease.终末期肾病中的动脉粥样硬化加速、血脂异常和氧化应激。
Curr Opin Nephrol Hypertens. 2002 Mar;11(2):141-7. doi: 10.1097/00041552-200203000-00003.
7
Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.降脂治疗对终末期肾病需血液透析患者减少心血管事件的影响。
Pharmacotherapy. 2010 Aug;30(8):823-9. doi: 10.1592/phco.30.8.823.
8
Lipid abnormalities associated with end-stage renal disease.与终末期肾病相关的脂质异常。
Semin Dial. 2006 Jan-Feb;19(1):32-40. doi: 10.1111/j.1525-139X.2006.00117.x.
9
Dyslipidemia in patients with chronic kidney disease.慢性肾脏病患者的血脂异常。
Rev Endocr Metab Disord. 2017 Mar;18(1):29-40. doi: 10.1007/s11154-016-9402-z.
10
Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.慢性肾脏病和终末期肾病患儿血脂异常的病因及管理
Pediatr Nephrol. 2015 Dec;30(12):2073-84. doi: 10.1007/s00467-015-3075-9. Epub 2015 Mar 24.

引用本文的文献

1
Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome.丁酸盐介导的对氧磷酶-1调节减轻多囊卵巢综合征大鼠模型的心肾代谢异常。
Cardiovasc Drugs Ther. 2024 Nov 16. doi: 10.1007/s10557-024-07649-y.
2
Does metabolic syndrome increase contrast-induced nephropathy in patients with normal renal function?代谢综合征是否会增加肾功能正常患者的对比剂肾病发生率?
J Res Med Sci. 2024 Jan 30;29:5. doi: 10.4103/jrms.jrms_136_21. eCollection 2024.
3
Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment.新型基于氧化 LDL 的腹膜透析患者临床标志物用于动脉粥样硬化风险评估。
Redox Biol. 2023 Aug;64:102762. doi: 10.1016/j.redox.2023.102762. Epub 2023 Jun 2.
4
Lipid status association with 25-hydroxy vitamin D: Cross sectional study of end stage renal disease patients.脂质状态与25-羟基维生素D的关联:终末期肾病患者的横断面研究
J Med Biochem. 2020 Sep 2;39(3):309-317. doi: 10.2478/jomb-2019-0032.
5
Dyslipidemia and Intraperitoneal Inflammation Axis in Peritoneal Dialysis Patients: A Cross-Sectional Pilot Study.腹膜透析患者的血脂异常与腹膜内炎症轴:一项横断面初步研究
Kidney Dis (Basel). 2020 Jan;6(1):35-42. doi: 10.1159/000503632. Epub 2019 Nov 6.
6
Association between Dyslipidemia and Peritoneal Dialysis Technique Survival.血脂异常与腹膜透析技术生存率之间的关联。
Open Access Maced J Med Sci. 2019 Jul 25;7(15):2467-2473. doi: 10.3889/oamjms.2019.664. eCollection 2019 Aug 15.
7
The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.血脂异常和氧化应激对肾功能障碍患者血管活性介质的影响。
Int Urol Nephrol. 2019 Dec;51(12):2235-2242. doi: 10.1007/s11255-019-02319-7. Epub 2019 Oct 22.
8
Metabolic Syndrome and the Iodine-Dose/Creatinine Clearance Ratio as Determinants of Contrast-Induced Acute Kidney Injury.代谢综合征和碘剂量/肌酐清除率比值与对比剂诱导的急性肾损伤的关系。
Cardiorenal Med. 2018;8(3):217-227. doi: 10.1159/000488374. Epub 2018 Jun 15.
9
Effects of dyslipidaemia on monocyte production and function in cardiovascular disease.血脂异常对心血管疾病中单核细胞生成和功能的影响。
Nat Rev Cardiol. 2017 Jul;14(7):387-400. doi: 10.1038/nrcardio.2017.34. Epub 2017 Mar 16.
10
Dyslipidemia in patients with chronic kidney disease: etiology and management.慢性肾脏病患者的血脂异常:病因与管理
Int J Nephrol Renovasc Dis. 2017 Feb 7;10:35-45. doi: 10.2147/IJNRD.S101808. eCollection 2017.

本文引用的文献

1
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.使用强效他汀类药物与急性肾损伤入院率:行政数据库的多中心回顾性观察性分析。
BMJ. 2013 Mar 18;346:f880. doi: 10.1136/bmj.f880.
2
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.HPS2-THRIVE 随机安慰剂对照试验纳入 25673 例 ER 烟酸/拉罗匹仑的高危患者:试验设计、预先指定的肌肉和肝脏结局以及停止研究治疗的原因。
Eur Heart J. 2013 May;34(17):1279-91. doi: 10.1093/eurheartj/eht055. Epub 2013 Feb 26.
3
Effects of dalcetrapib in patients with a recent acute coronary syndrome.近期急性冠脉综合征患者应用达塞曲匹的效果。
N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.
4
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.烟酸在接受强化他汀类药物治疗的低 HDL 胆固醇水平患者中的应用。
N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15.
5
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.辛伐他汀联合依折麦布降低慢性肾脏病患者 LDL 胆固醇的效果(心脏和肾脏保护研究):一项随机安慰剂对照试验。
Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.
6
Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization.他汀类药物对胆固醇结晶和动脉粥样硬化斑块稳定性的影响。
Am J Cardiol. 2011 Jun 15;107(12):1710-7. doi: 10.1016/j.amjcard.2011.02.336. Epub 2011 Apr 18.
7
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.阿托伐他汀与血液透析 2 型糖尿病患者的低密度脂蛋白胆固醇。
Clin J Am Soc Nephrol. 2011 Jun;6(6):1316-25. doi: 10.2215/CJN.09121010. Epub 2011 Apr 14.
8
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.NLRP3 炎性小体对于动脉粥样硬化的形成是必需的,并且可以被胆固醇晶体激活。
Nature. 2010 Apr 29;464(7293):1357-61. doi: 10.1038/nature08938.
9
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.瑞舒伐他汀与血液透析患者的心血管事件
N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30.
10
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.瑞舒伐他汀预防C反应蛋白升高的男性和女性发生血管事件。
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.